Endocannabinoids control spasticity in a multiple sclerosis model

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Spasticity is a common and debilitating symptom in multiple sclerosis (MS).
• A mouse model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) exhibits spasticity similar to MS.
• Endocannabinoids, such as anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), and palmitoylethanolamide (PEA) are implicated in neurological function.

Purpose of the Study:

• To investigate the role of the endocannabinoid system in spasticity associated with experimental autoimmune encephalomyelitis.
• To explore the therapeutic potential of modulating endocannabinoid levels for spasticity management.

Main Methods:

• Analysis of endocannabinoid and related lipid levels in brain tissue from spastic and non-spastic CREAE mice.
• Administration of exogenous endocannabinoids and PEA to assess their effect on spasticity.
• Treatment with selective inhibitors of endocannabinoid re-uptake and hydrolysis to evaluate spasticity amelioration.

Main Results:

• Increased levels of anandamide (AEA), 2-arachidonoyl glycerol (2-AG), and palmitoylethanolamide (PEA) were found in nerve-damaged areas of spastic CREAE mice.
• Exogenous administration of AEA, 2-AG, and PEA reduced spasticity.
• Inhibitors targeting endocannabinoid metabolism significantly ameliorated spasticity, comparable to cannabinoid receptor agonists.

Conclusions:

• The endocannabinoid system tonically controls spasticity in this MS model.
• Modulating endogenous endocannabinoid levels represents a novel therapeutic avenue for multiple sclerosis and other neuromuscular disorders.
• These agents may offer spasticity relief with reduced psychotropic side effects.